FierceBiotech’s hotlist of 15 for 2017

FierceBiotech’s hotlist of 15 for 2017

  • Axial Biotherapeutics
  • Aravive Biologics
  • BlackThorn Therapeutics
  • Gritstone Oncology
  • Magenta Therapeutics
  • PMV Pharma
  • PsiOxus Therapeutics
  • Relay Therapeutics
  • Repare Therapeutics
  • Rubius Therapeutics
  • Tango Therapeutics
  • Turnstone Biologics
  • Vir Biotechnology
  • Vivet Therapeutics
  • Vividion Therapeutic
Read more

Gene Therapy for Osteoarthritis cure.

South Korea OKs First-in-Class Gene Therapy for Osteoarthritis

South Korea’s Ministry of Food and Drug Safety said today that it has approved the country’s first gene therapy for osteoarthritis, the lead product candidate of a Maryland-based regenerative medicine company.

Invossa-K Inj. was developed by Maryland-based TissueGene, whose Korean licensee, Kolon Life Sciences, won approval for the injectable treatment. According to the company, Invossa is a first-in-class cell-mediated gene therapy designed to treat moderate (Kellgren and Lawrence grade 3) knee osteoarthritis through regeneration of cartilage.

Invossa uses allogeneic human cartilage cells

Read more

Whats is Optogenetics

From Wikipedia, the free encyclopedia
Optogenetics (from Greek optikós], meaning “seen, visible”) is a biological technique which involves the use of light to control cells in living tissue, typically neurons, that have been genetically modified to express light-sensitive ion channels. It is a neuromodulation method employed in neuroscience that uses a combination of techniques from optics and genetics to control and monitor the activities of individual neurons in living tissue—even within freely-moving animals—and to precisely measure the effects of those manipulations in real-time.[1] The key reagents used in optogenetics … Read more

Hemophilia B cure by gene therapy

Hemophilia B gene therapy pipeline
Company Project Mechanism Notes Trial details
Baxalta (Shire) BAX 335 AAV8-Padua FIX Phase III to start 2016 NCT01687608
UniQure/Chiesi AMT-060 AAV5-wild-type FIX Low-dose phase I/II data presented at EHA; high-dose data H2 2016 NCT02396342
Spark/Pfizer SPK-9001 Bio-engineered AAV-Padua FIX Low-dose phase I/II data presented at EHA NCT02484092
Dimension Therapeutics/ Regenxbio DTX101 AAVrh10-wild-type FIX Initial phase I/II data due H2 2016 NCT02618915
Sangamo Biosciences SB-FIX In vivo protein replacement using zinc finger nucleases Phase I trial started in 2016 NCT02695160
Freeline Therapeutics hemophilia B Gene
Read more

Gene therapy for osteoarthritis ?

GeneQuine develops drugs that are based on gene therapy. The concept of gene therapy is to introduce genetic material into the patient’s own cells in the body. The cells produce then a therapeutic protein according to the template that the introduced genetic material (DNA) provides

GeneQuine is focused on the development of gene therapy agents for the treatment of osteoarthritis. Osteoarthritis is a degenerative joint disorder characterized by cartilage loss and inflammation. Patients affected by osteoarthritis experience joint pain as well as swelling and stiffness of the joints leading to … Read more